Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Finch Therapeutics Group, Inc. (FNCH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.6400-0.0100 (-0.61%)
At close: 04:00PM EDT
1.8000 +0.16 (+9.76%)
After hours: 04:40PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close1.6500
Open1.6400
Bid1.5800 x 1100
Ask1.6500 x 1000
Day's Range1.5800 - 1.7000
52 Week Range1.5800 - 17.3900
Volume51,376
Avg. Volume49,038
Market Cap78.209M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.4450
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FNCH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Finch Therapeutics Group, Inc.
    Daily – Vickers Top Buyers & Sellers for 03/26/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Zacks

    Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why

    Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • American City Business Journals

    After Takeda ends collaboration, microbiome startup Finch Therapeutics cuts 50 jobs

    In an emailed statement, Finch Therapeutics CEO Mark Smith told the Boston Business Journal that most impacted team members are based in Massachusetts.

  • GlobeNewswire

    Finch Therapeutics Provides Business Update

    SOMERVILLE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 37% as part of an ongoing strategic review of its business and portfolio. This decision follows Finch’s recent announcement that it is asses

Advertisement
Advertisement